The SIL index is a simple and objective prognostic indicator in diffuse large B-cell lymphoma.
We previously developed a prognostic index, SIL, which includes advanced stage (S), soluble interleukin-2 receptor level (I), and elevated lactate dehydrogenase level (L) in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone (R-CHOP). This time we evaluated the index in a larger cohort and its utility in the risk stratification. The above three factors were independent risk of progression-free survival (PFS). Five-year PFS rates in the standard-risk (SIL index: 0 or 1, n = 367) and high-risk groups (SIL index: 2 or 3, n = 205) were 79% and 53%, respectively (p < 0.0001). When the patients were divided by age (≤60 years and >60 years), the SIL index was a good prognostic indicator for PFS in both groups as well as divided by the number of extranodal involvement site (0-1 and >1). The SIL index is a simple and objective prognostic indicator in DLBCL.
a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Naoto
N
Tomita
b Department of Hematology , Yokosuka City Hospital , Yokosuka , Japan.
Taisei
T
Suzuki
c Department of Hematology/Immunology , Fujisawa City Hospital , Fujisawa , Japan.
Kazuho
K
Miyashita
d Department of Medical Oncology , Kanagawa Cancer Center , Yokohama , Japan.
Wataru
W
Yamamoto
e Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
Kenji
K
Motohashi
a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Takayoshi
T
Tachibana
d Department of Medical Oncology , Kanagawa Cancer Center , Yokohama , Japan.
Hirotaka
H
Takasaki
c Department of Hematology/Immunology , Fujisawa City Hospital , Fujisawa , Japan.
Rika
R
Kawasaki
e Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
Maki
M
Hagihara
f Department of Hematology/Oncology , Yamato Municipal Hospital , Yamato , Japan.
Chizuko
C
Hashimoto
g Department of Internal Medicine , Yokohama Ekisaikai Hospital , Yokohama , Japan.
Sachiya
S
Takemura
h Department of Hematology , Shizuoka Red Cross Hospital , Shizuoka , Japan.
Hideyuki
H
Koharazawa
a Department of Internal Medicine and Clinical Immunology , Yokohama City University Graduate School of Medicine , Yokohama , Japan.
Etsuko
E
Yamazaki
h Department of Hematology , Shizuoka Red Cross Hospital , Shizuoka , Japan.
Jun
J
Taguchi
c Department of Hematology/Immunology , Fujisawa City Hospital , Fujisawa , Japan.
Katsumichi
K
Fujimaki
i Department of Hematology , Saiseikai Yokohama Nanbu Hospital , Yokohama , Japan.
Hiroyuki
H
Fujita
d Department of Medical Oncology , Kanagawa Cancer Center , Yokohama , Japan.
Rika
R
Sakai
e Department of Hematology , Yokohama City University Medical Center , Yokohama , Japan.
Shin
S
Fujisawa
d Department of Medical Oncology , Kanagawa Cancer Center , Yokohama , Japan.
Shigeki
S
Motomura
j Department of Hematology, Endocrinology, and Metabolism , Niigata University Faculty of Medicine , Niigata , Japan.
Keisuke
K
Kawamoto
j Department of Hematology, Endocrinology, and Metabolism , Niigata University Faculty of Medicine , Niigata , Japan.
Hirohito
H
Sone
j Department of Hematology, Endocrinology, and Metabolism , Niigata University Faculty of Medicine , Niigata , Japan.
Jun
J
Takizawa
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D015415:Biomarkers; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D045022:Lactate Dehydrogenases / Q000097:blood*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000097:blood*; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects / Q000627:therapeutic use; D055815:Young Adult
D058846:Antibodies, Monoclonal, Murine-Derived; D015415:Biomarkers; C571759:R-CHOP protocol; D015375:Receptors, Interleukin-2; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D045022:Lactate Dehydrogenases; D011241:Prednisone
Diffuse large B-cell lymphoma; R-CHOP; SIL index; prognosis; soluble interleukin-2 receptor